GeneNews Announces Q4 and Full Year 2014 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
GeneNews Announces Q4 and Full Year 2014 Financial Results
  • More than 46,300 tests were processed by the Company's joint-venture, Innovative Diagnostic Laboratory, LLP ("IDL") in the fourth quarter; with more than 150,000 in its first full year - 65,000 of those being ColonSentry®.
  • In-licensed two innovative new biomarker assays that aid physicians in identifying those females at highest risk for breast cancer.
  • Brought vital functions such as marketing, human resources, reimbursement and finance in-house at IDL to complement lab operations.
  • Subsequent to year-end, veteran medical/diagnostic industry reimbursement executive, Karl Florence, appointed to senior management team.

TORONTO, March 31, 2015 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX: GEN ) ("GeneNews" or the "Company") today reported operational and financial results for the three-month and full year period ended December 31, 2014 and provided a further progress update on IDL's operations.

Fourth Quarter and Full Year 2014 Financial Results

All dollar amounts are expressed in Canadian currency unless otherwise indicated and results are reported in accordance with International Financial Reporting Standards.

With a successful limited scale launch of IDL's operations in the fourth quarter of 2013, full scale up activities began in Q1-2014, including growing IDL's lab capacity, increasing the size and scope of its sales organization and expanding the menu of novel, proprietary tests offered by it throughout the United States. In the first half of 2014, IDL's key priority was to add new customer accounts, together with rapid expansion of its sales force. 

For the second half of the year, and continuing in the first quarter of 2015, the primary focus shifted to the refinement of IDL's organizational structure, sales territory re-alignment and adding an additional third party specialty servicer to strengthen private payer reimbursement efforts.  During the fourth quarter of 2014 GeneNews also began to take a proactive role in bringing a number of vital functions, such as lab operations, human resources, finance, marketing and reimbursement in house directly at IDL, transitioning these responsibilities from Health Diagnostic Laboratory, Inc. ("HDL").

"We would like to thank HDL for its contributions in getting IDL's Richmond, Virginia lab established and fully operational," commented GeneNews' Executive Chairman, James Howard-Tripp. "Now, as we shift 100% of our focus toward continuing to build the business, we believe that the time is right for GeneNews to take greater leadership roles in driving IDL's success."

Mr. Howard-Tripp continued, "IDL's model is designed to help stratify commercial risk by leveraging multiple test offerings to provide a smoother growth curve and more predictable revenue stream. "That approach served us well in 2014. Despite the changes we were making to the overall operations and sales force at IDL, many of which impacted ColonSentry® numbers, total test volumes were 97,400 in H2-2014, up approximately 50% from 65,700 in the first half of the year."

Revenues earned by IDL for the year ended December 31, 2014 were approximately $10.2 million (US$9.1 million) with costs incurred of approximately $30.9 million (US$28.1 million), including a fourth quarter $5.5 million charge related to a shortfall in minimum PHI test volumes under its contract with Beckman Coulter Diagnostics, resulting in a loss of approximately $20.6 million (US$19.0 million). As GeneNews currently has joint control of IDL with its American partners, the Company accounts for its interest in IDL using the equity method. As such, GeneNews reflects its share of the total revenues less total expenses in its consolidated statements of loss and comprehensive loss, which was $5.3 million, limiting its share of these losses to GeneNews' total investment made in 2014 of $5.4 million.

"In many respects, we only just crossed the starting line at the beginning of 2014 with the initiation of full scale up activities at IDL," said Mr. Howard-Tripp. "The lab achieved stellar growth in its first year, processing more than 150,000 tests in total. Of those, more than 65,000 were ColonSentry®, the world's first blood test designed to assess an individual's current risk for colorectal cancer and guide high-risk patients to colonoscopy."

Mr. Howard-Tripp continued, "Other key achievements in 2014 included the addition of four new, innovative advanced cancer assays - EarlyCDT®-Lung, PHI, sphingotest® pro-NT and sphingotest® pro-ENK."

IDL estimates that approximately 70% of the patients that have elected to have the ColonSentry® test are covered by private insurers with the remainder of patients undergoing the test covered by Medicare.  Reimbursement from Medicare has not been forthcoming as ColonSentry® is not approved for coverage, unlike the other IDL tests. As a relatively new entity, IDL does not yet have a history of collections of invoiced test revenue and recognizes revenue only upon receipt of payment from its customers. As a result of customary lag times between when a test is processed and payment is received, IDL's test volumes to date are not yet fully reflected in its financial results. 

For the three months ended December 31, 2014, GeneNews' total revenues were approximately $701,000 as compared to $37,000 in the same period in 2013. The net loss for the fourth quarter of 2014 was approximately $2.3 million, or $0.04 loss per common share, as compared to a net loss of approximately $2.5 million, or $0.07 loss per common share, for Q4-2013.

For the year ended December 31, 2014, GeneNews reported a net loss of approximately $7.7 million or $0.14 loss per common share, as compared to a net loss of approximately $9.4 million, or $0.31 loss per common share for the year ended December 31, 2013. The approximate $1.7 million decrease in net loss was primarily due to an increase in total revenues in the current year, the elimination of research and development spending, and the non-recurring nature of restructuring and related costs that were recorded in 2013 and decreases in sales and marketing expenses. These factors were partially offset by an increase in our share of IDL losses and in general and administrative expenses.

As of December 31, 2014, GeneNews had approximately $2.7 million in cash and cash equivalents, which did not include approximately $1.5 million in total proceeds from February 2015 warrant exercises. 

The Company's financial statements and management's discussion and analysis are available on www.sedar.com .

IDL Progress Update

Over the course of the past few months, there have been numerous structural and management team changes designed to further position IDL for continued sales success and growth.

As announced in February 2015, a number of vital functions, such as lab operations, human resources, finance, marketing and reimbursement have been brought in-house at IDL. In addition, IDL recently appointed Karl Florence to its senior management team to head up reimbursement efforts. Mr. Florence's mandate will be leading IDL's payer access and reimbursement efforts. He has an accomplished history of reimbursement strategy development and operations success within the medical/diagnostic industry. Most recently, he served as the Director of Reimbursement for Vermillion, Inc. In a career that spans over 25 years of reimbursement management, Mr. Florence's previous reimbursement management experience includes senior positions at various other companies, including USGI Medical, Pathwork Diagnostics, DexComm, Inc., Novasys Medical, Inc. and Conceptus, Inc.

"Karl is a seasoned leader with a strong track record of helping bring novel diagnostic products to market," commented Mr. Howard-Tripp. "I have tremendous confidence in his ability to develop and execute a comprehensive reimbursement strategy for IDL, and in so doing, significantly improve our revenue collections." 

Other recent organizational changes have included Mr. Howard-Tripp and GeneNews' Chief Financial Officer and Treasurer, Leslie Auld, taking on additional responsibilities, concurrently assuming the positions of IDL's President and CFO, respectively. IDL is also recruiting a Chief Scientific Officer.

"As IDL continues to grow, it is important that its management team is optimally structured to support both its current business and its ability to offer physicians and their patients an expanding menu of advanced cancer tests," commented Mr. Howard-Tripp. "To that end, final preparations are being made to launch the sphingotest® breast cancer risk prediction assays early in the second quarter. And we are not stopping there. Indeed, we are in discussions with respect to in-licensing additional technologies in 2015."   

Mr. Howard-Tripp concluded, "2014 provided us with a solid foundation for continued growth and we are very excited about the opportunity we see ahead of us in 2015 and beyond.  As always, we look forward to updating our stakeholders as we progress."

About GeneNews

GeneNews is focused on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a primary focus on cancer-related indications. The Company's lead product, ColonSentry®, is the world's first blood test to assess an individual's current risk for colorectal cancer. In 2013, GeneNews created a U.S. joint venture, Innovative Diagnostic Laboratory, LLP ("IDL"), that it is committed to help become a leader in molecular diagnostics and personalized medicine, serving as a strong commercialization outlet for advanced cancer tests. Taking a multi-view approach to the diagnosis and treatment of cancer, IDL is working to assemble, through a combination of internal pipeline development, third-party licenses and potential acquisitions, a robust menu of novel, proprietary tests to be offered by it throughout the United States. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com  and www.MyInnovativeLab.com , respectively.

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as " expects " , " will " and similar expressions, which reflect the Company's current expectations regarding future events, including the launch of ColonSentry ® test across the United States and the assembling of a robust menu of other advanced cancer tests to be offered by IDL. The forward-looking statements involve risks and uncertainties, including market reaction to the launch of the ColonSentry ® test into new regions, that could cause the Company ' s actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law. 

Company Contact: James R. Howard-Tripp Executive Chairman Office: (905) 209-2030 Investor & Media Contact: Stephen Kilmer Office: (212) 618-6347 Mobile: (905) 906-6908

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 72

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 117

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 86

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 25

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Why Insurance Must Change as Family Assets Keep Growing

Updated Category News Views 32

A policy bought in the starter-home years can turn stale quietly while everything around it gets bigger, pricier and more complicated. That is the uncomfortable little truth behind Daniel C. DiCocco's discussion in HelloNation: families often treat insurance as a box checked long ago, even as they add property, savings, debt, children and fresh responsibilities. Static...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Earnings: Barfresh Food Group's Upcoming Report

Updated Category News Views 61

Anticipating Earnings: Barfresh Food Group's Upcoming Report Barfresh Food Group (NASDAQ: BRFH) is on the brink of releasing its quarterly earnings. Investors are keenly awaiting the announcement, scheduled for Thursday. As the date approaches, it is crucial to analyze the expectations and historical performance of the company. The consensus among analysts is that...

Continue Reading
Meta's Smart Glasses: AI Performance Lags Behind ChatGPT's

Updated Category News Views 563

Meta's AI Tools Tested Against ChatGPT Recently, Gene Munster from Deepwater Asset Management conducted a head-to-head comparison of Meta Platforms Inc.'s AI capabilities on its smart glasses and the performance of OpenAI's ChatGPT. His findings highlighted significant gaps between the two AI systems. ChatGPT Outshines Meta AI in Tests During the evaluation, Munster...

Continue Reading
Tractor Supply Company Expands Offerings with Allivet Acquisition

Updated Category News Views 79

Tractor Supply Company to Acquire Allivet Tractor Supply Company (NASDAQ: TSCO), the top retailer for rural lifestyle in the U.S., has made an exciting announcement regarding its latest acquisition. The company has signed a definitive agreement to acquire Allivet, an esteemed private online pharmacy specializing in pet and animal health. This strategic move aims to...

Continue Reading
20+ Companies Break Ground in Urticaria Treatment Innovations

Updated Category News Views 236

Overview of Urticaria Treatment Innovations Urticaria, commonly known as hives, is a skin condition characterized by raised, itchy welts that can vary in size and location. The increasing prevalence of urticaria has spurred significant growth in treatment options, with various companies leading clinical trials dedicated to developing new therapies. Factors contributing to...

Continue Reading
Alphabet's Unique AI Strategy: A Competitive Edge Over Rivals

Updated Category News Views 241

Alphabet's AI Transformation and Competitive Advantage Alphabet Inc. (NASDAQ: GOOGL), a leader in technology innovation, is transforming its approach to artificial intelligence. The company, trading at $319.08 per share and boasting a market capitalization of $3.79 trillion, is narrowing the valuation gap with notable competitors. Its advancements in Tensor Processing...

Continue Reading